Treasure hunt for human papillomaviruses in nonmelanoma skin cancers.

41:3-8. (4) Partin AW, Carter HB. Chan DW. Epstein JI, Oesteriing JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990:143:747-52. (5) Thalmann GN, Sikes RA, Chang S-M, Johnston DA, von Eschenbach AS, Chung LW. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801. (<5) La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM. et al. Effect of suramin on human prostate cancer cells in vitro. J Urol 1991:145:393-8. (7) Steinkampf R, Bordelon S, Klohs W. The lack of effect of suramin on prostate specific antigen secretion from human prostatic cancer LNCaP cells. Proc Am Assoc Cancer Res 1996;37:abstr 1667. (8) Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egonn MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995; 13:2944-53. (9) Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer [see comment citation in Medline]. J Clin Oncol 1993; 11:607-15. (10) Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-9. (//) Steiner MS, Seckin B, Anthony CT, Murphy B. Can prostate specific antigen be used as a valid endpoint for chemotherapy efficacy in advanced prostate cancer? Proc Am Assoc Cancer Res 1995;36:abstr 1245. (12) Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL Jr, et al. Sensitivities of human prostate tumor cell lines to the calcium influx inhibitor carboxyamidotriazole (CAI). Proc Am Assoc Cancer Res 1996; 37:abstr 1669. (13) Melchior S, Stone B, Santucci R, Brown L, True L, Daniel J, et al. Differentiation inducers phenylacetate and phenylbutyrate and their effects invitro and on the advanced prostate cancer (CaP) xenograft model LUCaP 23.1. Proc Am Assoc Cancer Res 19%;37:abstr498.